Sign inJoin waitlistJoin the waitlist

Michael Aaron Morse

Professor of Medicine · Duke University

Credentials: ·

History

Duke University
Present
Duke Department of Surgery
Present
Duke Cancer Institute
Present

Research

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
The Lancet Oncology · 2017 · 2,298 citations
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Journal of Clinical Oncology · 2018 · 1,662 citations
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
The Lancet Oncology · 2016 · 1,055 citations

Herbert Lyerly
148 papers · 7 as a resident
HH
Herbert Hurwitz
43 papers
Bryan Clary
22 papers · 6 as a resident
Douglas Tyler
22 papers
Paul Mosca
19 papers · 15 as a fellow
Hope Uronis
17 papers
Gerard Blobe
16 papers
JB
Johanna Bendell
16 papers · 5 as a fellow
Syed Zafar
14 papers
Brian Czito
13 papers
Theodore Pappas
12 papers
John Strickler
11 papers · 1 as a fellow

Clinical trials

Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
Principal investigator · Completed · Phase 1, Phase 2
Duke University
2017–2022